Gemfibrozil, stretching arms beyond lipid lowering

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 3, 2009, Pages 339-351

  Roy, Avik ^a   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gemfibrozil; Human disorders; Inflammation; Signal transduction

Indexed keywords

CELL ADHESION MOLECULE; CLOFIBRATE; CYTOKINE; FENOFIBRATE; FREE RADICAL; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; VERY LONG CHAIN FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL CONTACT; CELL MIGRATION; CELLULAR IMMUNITY; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; FATTY ACID OXIDATION; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; LIPID STORAGE; LIPOPROTEIN SYNTHESIS; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CELL COMMUNICATION; CELL MOVEMENT; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TRIGLYCERIDES;

EID: 70350671530     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970902785253     Document Type: Review

References (99)

1. Hodges, R.M. Gemfibrozil-A new lipid lowering agent. Proc. Royal Soc.Med. 1976, 69 Suppl 2, 1-2.
2. Betteridge, D.J., Higgins, M.J., Galton, D.J. Properties of sterol biosynthesis in human leukocytes, effects of gemfibrozil. Proc. Royal Soc. Med.1976, 69 Suppl 2, 104-106.
3. Auwerx, J. Regulation of gene expression by fatty acids and fibric acid derivatives, an integrative role for peroxisome proliferator activated receptors. The Belgian Endocrine Society Lecture 1992. Hormone Res. 1992, 38(5-6), 269-277.
4. Xu, H.E., Lambert, M.H., Montana, V.G., et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. NAS USA . 2001, 98(24), 13919-13924.
5. Hostetler, H.A., Petrescu, A.D., Kier, A.B., Schroeder, F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands. J Biol Chem. 2005, 280(19), 18667-18682.
6. Pawar, A., Jump, D.B. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J. Biol. Chem . 2003, 278(38), 35931-35939.
7. Gottlicher, M., Demoz, A., Svensson, D., Tollet, P., Berge, R.K., Gustafsson, J.A. Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor. Biochem. Pharmacol. 1993, 46(12), 2177-2184.
8. Scatena, R., Bottoni, P., Martorana, G.E., et al. Mitochondria, ciglitazone and liver, a neglected interaction in biochemical pharmacology. Eur. J. Pharmacol . 2007, 567(1-2), 50-58.
9. Zoete, V., Grosdidier, A., Michielin, O. Peroxisome proliferator- activated receptor structures, ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta. 2007, 1771(8), 915-925.
10. Nash, D.T. Hyperlipoproteinemia, atherosclerosis and gemfi- brozil. Angiology. 1982, 33(9), 594-602.
11. DeSalcedo, I., Gorringe, A.L., Silva, J.L., Santos, J.A. Gemfibrozil in a group of diabetics. Proc.Royal Soc.Med. 1976, 69 Suppl 2, 64-70.
12. Miller-Blair, D., White, R., Greenspan, A. Acute gout involving the acromioclavicular joint following treatment with gemfibrozil. J. Rheum. 1992, 19(1), 166-168.
13. Dellavalle, R.P., Nicholas, M.K., Schilling, L.M. Melanoma chemoprevention, a role for statins or fibrates? Am. J. Therapeutics . 2003, 10(3), 203-210.
14. Dasgupta, S., Roy, A., Jana, M., Hartley, D.M., Pahan, K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Molec. Pharmacol. 2007, 72(4), 934-946.
15. Strauss, J.F., Liu, P., Christenson, L.K., Watari, H. Sterols and intracellular vesicular trafficking, lessons from the study of NPC1. Steroids. 2002, 67(12), 947-951.
16. Ioannou, Y. Multidrug permeases and subcellular cholesterol transport. Nature Rev. Molec. Cell Biol. 2001, 2(9), 657-668.
17. Schmitz, G., Grandl, M. Lipid homeostasis in macrophages - Iimplications for atherosclerosis. Rev Physiol Biochem. Pharmacol. 2008, 160, 93-125.
18. Chinetti-Gbaguidi, G., Rigamonti, E., Helin, L., et al. Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 2005, 46(12), 2717-2725. (Pubitemid 43107484)
19. Rigamonti, E., Chinetti-Gbaguidi, G., Staels, B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterio., Thromb. Vasc. Biol. 2008, 28(6), 1050-1059.
20. Hossain, M.A., Tsujita, M., Gonzalez, F.J., Yokoyama, S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J. Cardiovasc. Pharmacol. 2008, 51(3), 258-266.
21. Oram, J.F., Lawn, R.M. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 2001, 42(8), 1173-1179.
22. Venkateswaran, A., Laffitte, B.A., Joseph, S.B., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. NAS USA 2000, 97(22), 12097-12102.
23. Forcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., Beylot, M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002, 51(12), 3486-3491.
24. van Meer, G. Caveolin, cholesterol, and lipid droplets? J. Cell Biol. 2001, 152(5), F29-34.
25. Lee, O., Chang, C.C., Lee, W., Chang, T.Y. Immunodepletion experiments suggest that acyl-coenzyme A, cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J. Lipid Res. 1998, 39(8), 1722-1727.
26. Chinetti, G., Lestavel, S., Fruchart, JC., Clavey, V., Staels, B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ. Res. 2003, 92(2), 212-217.
27. Mandel, H., Getsis, M., Rosenblat, M., Berant, M., Aviram, M. Reduced cellular cholesterol content in peroxisome-deficient fibroblasts is associated with impaired uptake of the patient's low density lipoprotein and with reduced cholesterol synthesis. J. Lipid Res. 1995, 36(6), 1385-1391.
28. Hashimoto, F., Hamada, S., Hayashi, H. Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism. Biol. Pharmaceut. Bull. 1997, 20(4), 315-321.
29. Aoyama, T., Peters, J.M., Iritani, N., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998, 273(2), 5678-5684.
30. Jones, D.P. Intracellular catalase function, analysis of the catalatic activity by product formation in isolated liver cells. Arch. Biochem. Biophys. 1982, 214(2), 806-814.
31. Brady, P.S., Ramsay, R.R., Brady, L.J. Regulation of the long-chain carnitine acyltransferases. FASEB J. 1993, 7(11), 1039-1044.
32. Kamijo, K., Taketani, S., Yokota, S., Osumi, T., Hashimoto, T. The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily. J. Biol. Chem. 1990, 265(8), 4534-4540.
33. Latruffe, N., Cherkaoui Malki, M., Nicolas-Frances, V., Clemencet, M.C., Jannin, B., Berlot, J.P. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases. Biochem. Pharmacol. 2000, 60(8), 1027-1032.
34. Burns, K.A., Vanden Heuvel, J.P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta . 2007, 1771(8), 952-960.
35. Jin, F.Y., Kamanna, V.S., Chuang, M.Y., Morgan, K., Kashyap, M.L. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler., Thromb., Vasc. Biol. 1996, 16(8), 1052-1062.
36. Saku, K., Gartside, P.S., Hynd, B.A., Kashyap, M.L. Mechanism of action of gemfibrozil on lipoprotein metabolism. J. Clin. Invest. 1985, 75(5), 1702-1712.
37. Xiao, J., Zhang, F., Wiltshire, S., et al. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population. Atherosclerosis. 2008, 199(2), 333-339.
38. Robins, S.J., Collins, D., Wittes, J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events, VA-HIT, a randomized controlled trial. JAMA. 2001, 285(12), 1585-1591.
39. Frick, M.H., Elo, O., Haapa, K., et al. Helsinki Heart Study, primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med.1987, 317(20), 1237-1245.
40. Pahan, K., Jana, M., Liu, X., Taylor, BS., Wood, C., Fischer, S.M. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J. Biol. Chem. 2002, 277(48), 45984-45991.
41. Xu, J., Racke, M.K., Drew, P.D. Peroxisome proliferator- activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS, relevance to multiple sclerosis. J. Neurochem. 2007, 103(5), 1801-1810.
42. Xu, J., Chavis, J.A., Racke, M.K., Drew, P.D. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J. Neuroimmunol. 2006, 176(12), 95-105.
43. Jana, M., Jana, A., Liu, X., Ghosh, S., Pahan, K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J. Immunol. 2007, 179(6), 4142-4152.
44. Yang, Y., Gocke, AR., Lovett-Racke, A., Drew, PD., Racke, M.K. PPAR Alpha regulation of the immune response and autoimmune encephalomyelitis. PPAR Res. 2008, 2008,546753.
45. Drew, P.D., Xu, J., Storer, P.D., Chavis, J.A., Racke, M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disorders. Neurochem. Int. 2006, 49(2), 183-189
46. Bloomfield Rubins, H., Davenport, J., Babikian, V., et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001, 103(23), 2828-2833.
47. Cunard, R. The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Investigat. Drugs. 2005, 6(5), 467-472.
48. Calkin, A.C., Cooper, M.E., Jandeleit-Dahm, K.A., Allen, T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 2006, 49(4), 766-774.
49. Watkins, B.A., Dorn, H.H., Kelly, W.B., et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science. 1990, 249(4968), 549-553.
50. Pencalet, P., Serguera, C., Corti, O., Privat, A., Mallet, J., Gimenez, Ribotta M. Integration of genetically modified adult astrocytes into the lesioned rat spinal cord. J. Neurosci. Res. 2006, 83(1), 61-67.
51. Roy, A., Fung, Y.K., Liu, X., Pahan, K. Up-regulation of microglial CD11b expression by nitric oxide. J. Biol. Chem. 2006, 281(21), 14971-14980.
52. Brahmachari, S., Fung, Y.K., Pahan, K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J. Neurosci2006, 26(18), 4930-4939.
53. Pahan, K., Sheikh, F.G., Liu, X., Hilger, S., McKinney, M., Petro, T.M. Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J. Biol. Chem. 2001, 276(11), 7899-7905.
54. Jackson, T.C., Mi, Z., Bastacky, S.I., McHale, T., Melhem, M.F., Sonalker, P.A., Tofovic, S.P., Jackson, E.K. PPAR alpha agonists improve renal preservation in kidneys subjected to chronic in vitro perfusion: interaction with mannitol. Transplant Intern. 2007, 20(3), 277-290
55. Okamoto, H., Kamatani, N. Successful treatment with fenofi- brate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63(8), 1002-1003.
56. Deans, K.A., Sattar, N. "Anti-inflammatory" drugs and their effects on type 2 diabetes. Diabetes Technol. Therapeut. 2006, 8(1), 18-27.
57. Neve, B.P., Fruchart, J.C., Staels, B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 2000, 60(8), 1245-1250.
58. Dasgupta, S., Zhou, Y., Jana, M., Banik, N.L., Pahan, K. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J. Immunol. 2003, 170(7), 3874-3882
59. Racke, M., Gocke, A., Muir, M., Diab, A., Drew, P., Lovett- Racke, A. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutrition. 2006, 136, 700-703.
60. Dasgupta, S., Jana, M., Liu, X., Pahan, K. Myelin basic proteinprimed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J. Biol. Chem. 2002, 277(42), 39327-39333
61. Roy, A., Liu, X., Pahan, K. Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin. J. Biol. Chem. 2007, 282(44), 32222-32232.
62. Heyworth, P.G., Bohl, B.P., Bokoch, G.M., Curnutte, J.T. Rac translocates independently of the neutrophil NADPH oxidase components p47phox and p67phox. Evidence for its interaction with flavocytochrome b558. J. Biol. Chem. 1994, 269(49), 30749-30752.
63. Kleinberg, M.E., Malech, H.L., Mital, D.A., Leto, T.L. p21rac does not participate in the early interaction between p47-phox and cytochrome b558 that leads to phagocyte NADPH oxidase activation in vitro. Biochemistry. 1994, 33(9), 2490-2495.
64. Kervinen, H., Huittinen, T., Vaarala, O., et al. Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk. Atherosclerosis. 2003, 169(2), 339-344.
65. Aviram, M., Rosenblat, M., Bisgaier, C.L., Newton, R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998, 138(2), 271-280.
66. Balogh, Z., Seres, I., Harangi, M., Kovacs, P., Kakuk, G., Paragh, G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab. 2001, 27(5), 604-610.
67. Mowri, H.O., Frei, B., Keaney, J.F. Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radical Biol. Med. 2000, 29(9), 814-824.
68. Wolff, S.P., Jiang, Z.Y., Hunt, J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad. Biol. Med. 1991, 10(5), 339-352.
69. Requena, J.R., Fu, M.X., Ahmed, M.U., et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J. 1997, 322 ( Pt 1), 317-325.
70. Hunter, M.I., Nlemadim, B.C., Davidson, D.L. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem. Res.1985, 10(12), 1645-1652.
71. Toshniwal, P.K., Zarling, E.J. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem. Res. 1992, 17(5), 205-207.
72. Yoshida, H., Ishikawa, T., Ayaori, M., et al. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein, a randomized, double-blind, placebo-controlled study. Atherosclerosis. 1998, 139(1), 179-187.
73. Gouedard, C., Koum-Besson, N., Barouki, R., Morel, Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofi- brate and statins. Molec. Pharmacol. 2003, 63(4), 945-956.
74. Marx, N., Sukhova, G.K., Collins, T., Libby, P., Plutzky, J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999, 99(24), 3125-3131.
75. Marchesi, S., Lupattelli, G., Lombardini, R., et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J. Clin. Pharmacy Therapeut. 2003, 28(5), 419-424.
76. Pasceri, V., Cheng, J.S., Willerson, J.T., Yeh, E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti- atherosclerosis drugs. Circulation. 2001, 103(21), 2531-2534.
77. Han, S.H., Quon, M.J., Koh, K.K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension. 2005, 46(5), 1086-1092.
78. Pahan, K. Lipid-lowering drugs. Cellular Molec. Life Sci. 2006, 63, 1165-1178.
79. Ye, H.J., Zhao, S.P. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. Med. Hypotheses. 2006, 66(3), 495-500.
80. Ryoo, S.W., Kim, D.U., Won, M., et al. Native LDL induces interleukin-8 expression via H2O2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells. Cardiovasc Res. 2004, 62(1), 185-193.
81. Ryoo, S., Won, M., Kim, D.U., et al. PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. Biochem. Biophys. Res. Communs. 2004, 318(2), 329-334.
82. Sumanasekera, W.K., Tien, E.S., Davis, J.W., Turpey, R., Perdew, G.H., Vanden Heuvel, JP. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator- activated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry. 2003, 42(36), 10726-10735.
83. Hossain, M.A, Tsujita, M., Gonzalez, F.J., Yokoyama, S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J. Cardiovasc. Pharmacol. 2008, 51(3):258-266
84. Tordjman, K., Bernal-Mizrachi, C., Zemany, L., et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 2001, 107(8)(7), 1025-1034.
85. Oshio, H., Abe, T., Onogawa, T et al. Peroxisome proliferatoractivated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. J. Gastroenterol. 2008, 43, 538-549.
86. Mohan, W.S., Chen, Z.Q., Zhang, X., et al. Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter, role of gemfibrozil. J. Lipid Res. 1998, 39(2), 255-267.
87. Maher, J.M., Cheng, X., Slitt, A.L., Dieter, M.Z., Klaassen, C.D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Disposition. 2005, 33(7), 956-962
88. Shek, A., Ferrill, M.J. Statin-fibrate combination therapy. Ann. Pharmacother. 2001, 35(7-8), 908-917.
89. Broeders, N., Knoop, C., Antoine, M., Tielemans, C., Abramowicz, D. Fibrate-induced increase in blood urea and creatinine, is gemfibrozil the only innocuous agent? Nephrol. Dialysis Transplantation 2000, 15(12), 1993-1999.
90. Dube, M., Fenton, M. Lipid abnormalities. Clin. Infect. Dis. 2003, 36(Suppl 2), S79-83.
91. Knauf, H., Kolle, E.U., Mutschler, E. Gemfibrozil absorption and elimination in kidney and liver disease. Klinische Wochenschrift. 1990, 68(13), 692-698.
92. Saadi, H.F., Kurlander, D.J., Erkins, J.M., Hoogwerf, B.J. Severe hypertriglyceridemia and acute pancreatitis during pregnancy, treatment with gemfibrozil. Endocr. Pract. 1999, 5(1), 33-36.
93. Freeman, S.R., Drake, A.L., Heilig, L.F., et al. Statins, fibrates, and melanoma risk, a systematic review and meta-analysis. J. NCI. 2006, 98(21), 1538-1546.
94. Leiss, O., von Bergmann, K., Gnasso, A., Augustin, J. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. Metabolism. 1985, 34(1), 74-82.
95. Reddy, J.K., Mannaerts, G.P. Peroxisomal lipid metabolism. Ann. Rev. Nutrition. 1994, 14, 343-370.
96. Braun, L., Mile, V., Schaff, Z., et al. Induction and peroxisomal appearance of gulonolactone oxidase upon clofibrate treatment in mouse liver. FEBS Lett. 1999, 458(3), 359-362.
97. Gonzalez, F.J., Peters, J.M., Cattley, R.C. Mechanism of action of the nongenotoxic peroxisome proliferators, role of the peroxisome proliferator-activator receptor alpha. J. NCI. 1998, 90(22), 1702-1709.
98. Asif, A.R., Armstrong, V.W., Voland, A., Wieland, E., Oellerich, M., Shipkova, M. Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie. 2007, 89(3), 393-402.
99. Thomas, B.F., Burgess, J.P., Coleman, D.P., Scheffler, N.M., Jeffcoat, A.R., Dix, K.J. Isolation and identification of novel metabolites of gemfibrozil in rat urine. Drug Metab. Disposit., Biol. Fate Chems. 1999, 27(1), 147-157.